Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-27T01:29:50.705Z Has data issue: false hasContentIssue false

Measuring Bias in Uncontrolled Brain Tumor Trials – to Randomize or Not to Randomize?

Published online by Cambridge University Press:  18 September 2015

William D. Irish
Affiliation:
Pittsburgh Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvannia
David R. Macdonald
Affiliation:
Departments of Clinical Neurological Sciences and Oncology, University of Western Ontario London Regional Cancer Centre, London, Ontario
J. Gregory Cairncross*
Affiliation:
Departments of Clinical Neurological Sciences and Oncology, University of Western Ontario London Regional Cancer Centre, London, Ontario
*
London Regional Cancer Centre, 790 Commissioners Road, East, London, Ontario, Canada N6A 4L6
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Purpose:

To help investigators decide if new therapies for glioma warrant definitive evaluation in randomized studies we have been developing a method for assessing the degree to which patient selection may have enhanced the results of uncontrolled treatment trials. In this study, we analyzed the impact of case selection on the survival of patients with malignant glioma receiving adjuvant stereotactic radiosurgery, a promising therapy reserved for those with small tumors and good performance status.

Methods:

Following published eligibility criteria we simulated the patient selection process for stereotactic radiosurgery given as a boost at the conclusion of conventional radiotherapy. Eligible patients were culled from a pre-existing clinical/imaging database of 101 consecutive conventionally-treated patients with biopsy-proven malignant glioma and known survival times. Median durations of survival and 2- and 3-year survival rates were determined for those judged eligible or ineligible for stereotactic radiosurgery.

Results:

Twenty-seven percent of patients were deemed eligible for stereotactic radiosurgery, eligible patients had more favorable prognostic factors and significantly longer median survival than ineligible patients (23.4 vs. 8.6 months; 2-year rate, 48% vs. 15%; 3-year rate, 30% vs. 7%); eligible patients also had a longer median survival than the entire group of unselected patients (23.4 vs. 11.4 months). Radiosurgery-eligible, conventionally-treated patients with glioblastoma multiforme and a group of radiosurgery-treated patients at a special referral center had similar median survival times (16.4 vs. 19.7 months).

Conclusion:

We provide additional evidence for selection bias in uncontrolled trials of stereotactic radiosurgery and by simulating the selection process accurately have detected a larger bias effect than noted previously. Judging from experience with interstitial radiation and intraarterial chemotherapy where substantial selection bias also occurred and randomized controlled trials proved disappointing, we conclude that a phase III study of stereotactic radiosurgery for malignant glioma is unlikely to yield a positive result and may not be necessary.

Type
Original Articles
Copyright
Copyright © Canadian Neurological Sciences Federation 1997

References

1.Winger, MJ, Macdonald, DR, Schold, SC, Cairncross, JG. Selection bias in clinical trials of anaplastic glioma. Ann Neurol 1989; 26: 531534.CrossRefGoogle ScholarPubMed
2.Florell, RC, Macdonald, DR, Irish, WD, et al. Selection bias, survival, and brachytherapy for glioma. J Neurosurg 1992; 76: 179183.CrossRefGoogle ScholarPubMed
3.Kirby, S, Brothers, M, Irish, W, et al. Evaluating glioma therapies – modeling treatments and predicting outcomes. J Natl Cancer Inst 1995; 87: 18841888.CrossRefGoogle ScholarPubMed
4.Loeffler, JS, Alexander, E, Shea, WM, et al. Radiosurgery as part of the initial management of patients with malignant gliomas. J Clin Oncol 1992; 10: 13791385.CrossRefGoogle ScholarPubMed
5.Loeffler, JS, Shrieve, DC, Wen, PY, et al. Radiosurgery for intracranial malignancies. Sem Radiat Oncol 1995; 5: 225234.CrossRefGoogle ScholarPubMed
6.Kaplan, EL, Meier, P.Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 437481.CrossRefGoogle Scholar
7.Breslow, NE. A generalized Kurskel-Wallis test for comparing K samples subject to unequal patterns of censorship. Biometrika 1970; 57: 579594.CrossRefGoogle Scholar
8.Curran, WJ, Scott, CB, Horton, J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85: 704710.CrossRefGoogle ScholarPubMed
9.Curran, WJ, Scott, CB, Weinstein, AS, et al. Survival comparison of radiosurgery-eligible and -ineligible malignant glioma patients treated with hyperfractionated radiation therapy and carmustine: a report of Radiation Therapy Oncology Group 83-02. J Clin Oncol 1993; 11:857862.CrossRefGoogle ScholarPubMed
10.Sarkaria, MD, Mehta, MP, Loeffler, JS, et al. Radiosurgery in the initial management of malignant gliomas: survival comparison with the RTOG recursive partitioning analysis. Int J Radiat Oncol BiolPhys 1995;32:931941.CrossRefGoogle ScholarPubMed
11.Shapiro, WR, Green, SB, Burger, PC, et al. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma. J Neurosurg 1992; 76: 772781.CrossRefGoogle ScholarPubMed
12.Shapiro, WR, Green, S, Burger, P, et al. A randomized trial of interstitial radiotherapy (IRT) boost for the treatment of newly diagnosed malignant glioma (glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, malignant mixed glioma): BTCG Study 8701. Neurology 1994; 44 (Suppl 2): A263.Google Scholar